Abstract
Hidradenitis suppurativa (HS) is an inflammatory disease characterized by a recurrent‐remission trend and clinical lesions that range from asymptomatic to inflamed, deep‐seated nodules with scarring and suppuration. The aim of our study was to identify morphologic and vascular features of HS nodules by means of dynamic optical coherence tomography (D‐OCT) and to define if they are correlated to patient endotype and risk of disease progression. A set of standardized clinical pictures and D‐OCT images were acquired from 57 inflammatory nodules of 40 patients affected by HS. A set of 20 clinical and D‐OCT images were acquired from 20 healthy volunteers as a control group. The comparison of D‐OCT features among HS and control group was analysed. The correlation between HS patient endotype and D‐OCT features of the lesions was calculated. D‐OCT enabled to identify vascular and morphological aspects characterizing HS nodular inflammatory lesions. In addition, several D‐OCT features were significantly different among distinct disease endotypes. The characterization of HS nodular inflammatory lesions through D‐OCT, corresponding to blood vessel dilation and inflammatory associated hyper‐vascularization, may have important clinical consequences in the assessment of HS risk of progression, therapeutic decisions and treatment efficacy monitoring.
Keywords: endotypes, Hidradenitis suppurativa, optical coherence tomography, therapy, vascularization
1. INTRODUCTION
Hidradenitis suppurativa (HS) is a relapsing‐remitting inflammatory disease characterized by a progression of asymptomatic nodules to deep‐seated lesions and fistula formation that leads to suppuration and scarring, with functional limitation and aesthetic disadvantage. 1 , 2 The aetiology of HS is multifactorial and involves both genetic and environmental factors. The pathogenesis includes the following: follicular occlusion, altered immunological response and bacterial colonization; moreover, hormones, obesity and smoking contribute to disease worsening. 3 , 4 , 5
Current pathogenic models showed that HS starts around the hair follicle, indeed the first reported events are infundibular acanthosis, hyperkeratosis and local immune cell infiltration. 6 , 7 The infundibular changes induce follicular occlusion and a phlogistic reaction with eventual rupture of the epithelial capsule and bacterial proliferation. 6 , 7 , 8 , 9 These anatomic and inflammatory events lead to the formation of clinically visible dermal nodules and abscesses which may evolve into pus‐draining epithelialized sinus tracts, fistulas and eventually to fibrotic scarring. 7 , 8 , 9 , 10
HS diagnosis is clinical and relies on the presence of the following signs: typical lesions such as nodules, abscesses, tunnels and scars; localization mainly at the axillae and groin; and a relapsing‐remittent disease course. 11 , 12 Considerable variability occurs in the clinical presentation, disease severity and treatment response, with a broad spectrum of possible HS presentations and comorbidities. 8 , 13 , 14 , 15 Regarding possible risk factor for HS progression, several studies identified male sex, being overweight or obese, smoking, a long‐term history of the disease and the presence of lesions in the perianal, axillary and inframammary area as important prognostic elements. 16 , 17
Several phenotype classifications have been proposed, based mainly upon the clinical distribution of lesions and the lesion types (i.e. comedones, nodules and presence of scarring or tunnels). 8 , 18 Recently, Martorell and colleagues identified three HS endotypes: the follicular (FP), the inflammatory (IP) and the mixed phenotype (MP). 19 The FP is characterized by the presence of folliculitis with multiple comedones and phlogistic nodules that are not coalescing. On the contrary, IP is characterized by the presence of abscesses and thick fistular tracts that tends to coalesce into poorly defined inflammatory plaques, in the absence of folliculitis or comedones. The authors observed that these endotypes are associated with distinct clinical courses, in fact, while FP patients present an indolent disease, IP‐affected individuals often show a rapidly progressing course characterized by the formation of complex coalescent lesions over a short period of time. 19 Intriguingly the presence of IP disease was associated with increased cardiovascular risk, probably because of the presence of higher local and systemic inflammatory phenomena. 20
Dynamic optical coherence tomography (D‐OCT) is a novel non‐invasive imaging technique based on the physical principle of low coherence interferometry that has been used for the diagnosis and characterization of skin cancers and inflammatory diseases. 21 , 22 , 23 It offers a fast and reliable evaluation of the epidermis and dermis up to 1 mm of depth, as well as the microvascular changes in blood flow, allowing an accurate morphological and a functional characterization of skin lesions. Indeed, en vivo blood flow can be visualized by means of cross‐sectional images. Recently, we described the morphologic and functional features of comedos, papules and pustules in acne, analysing their characteristics and describing their evolution from their genesis to their resolution, with non‐invasive imaging devices. 24 , 25 To our best knowledge, D‐OCT features of HS nodules have not yet been described.
The aim of our study was to assess and describe D‐OCT morphological features of nodular inflammatory HS lesions and to determine if different D‐OCT features were associated with a distinct phenotype of the disease.
2. MATERIALS AND METHODS
A retrospective case‐control study of HS patients and age‐ and sex‐matched control cohort was carried out at the Dermatology Department of the University of Modena and Reggio Emilia between January 2018 and June 2021. HS patients were selected based on active consent for both clinical and D‐OCT image acquisition with mild‐moderate disease, determined according to the HS‐Physician Global Assessment (PGA) severity scale 26 and the presence of at least 1 inflammatory HS nodule. Patients under any HS specific therapy during the 4 weeks before image acquisition were excluded. HS patients were furtherly classified into one of the endotypes previously described by Martorell et al. 19 D‐OCT images were acquired from nodular inflammatory lesions that were selected according to clinical characteristics. Epidemiologic and clinical data were recorded in a dedicated database and analysed.
Standardized clinical pictures were acquired through the Canon G16® (Canon Inc., Canon Park, Melville, NY 11747, USA) and the Canfield Close‐up Scale® (Canfield Imaging Systems, Fairfield, NJ, USA). D‐OCT images were acquired with the VivoSight® D‐OCT (Michelson Diagnostics Ltd, Eclipse House, Sittingbourne Road, Maidstone, Kent, UK). Vertical and horizontal‐plane OCT images, along with functional data (blood flow information) are immediately displayed on the structural OCT images as an overlay, so that the relationship between the vessels and the structural images can be visualized in real time. Areas of motion are coloured red. A “stack” of 120 D‐OCT images was captured for each lesion to form a 3‐dimensional (3D) “data block.” D‐OCT images were processed using an automatic software protocol and 3D image reconstruction software. 27
The control group included 20 age‐ and sex‐matched volunteers, who consented to healthy skin D‐OCT image acquisition of the axillary or groin regions.
The study was performed in conformity with the ethical guidelines of the Declaration of Helsinki and in compliance with the ethics committee approval (E.C. 444/2021).
2.1. D‐OCT descriptors
For the evaluation of D‐OCT images, qualitative and quantitative measurements were obtained. Two expert readers jointly retrospectively evaluated D‐OCT parameters, as follows: infundibular hyper‐keratinization, blurred dermal‐epidermal junction (DEJ), granular epidermis, amorphous material inside follicles, organized inflammatory infiltrate, threshold at 300 μm, threshold at 500 μm (Table 1).
TABLE 1.
Definition of morphologic and vascular D‐OCT features of HS nodules
D‐OCT features | Definition |
---|---|
Infundibular hyper‐keratinization | Thick linear hyper‐echogenic signal that persists among the corneum and increases at the infundibulum |
Blurred DEJ | Ill‐defined dermal–epidermal junction (without defined boundaries) |
Granular epidermis | Sand‐like hypo‐echogenic epidermis |
Clots of amorphous material inside follicles | Hyper‐echogenic plug inside the follicle |
Organized inflammatory infiltrate | Collection of organized hyper‐echogenic inflammatory material in the epidermis and the dermis |
Threshold at 300 μm | The evaluation of the amount of red pixel at 300 μm from the stratum corneum corresponding to vessel density. |
Threshold at 500 μm | The evaluation of the amount of red pixel at 500 μm from the stratum corneum corresponding to vessel density. |
2.2. Statistical analysis
Absolute and relative frequencies, mean and standard deviation (SD) for continuous measurements were calculated for each parameter. Frequencies and measurements of the D‐OCT patterns were determined and the following comparisons were performed: (1) HS nodules vs control group healthy skin; (2) direct comparison between phenotypes (FP vs IP vs MP). Student T‐test and Fisher exact test were calculated to compare continuous and nominal variables, respectively (SPSS v. 17 Inc., Chicago, IL, USA). Bonferroni adjustment was used (critical α = 0.05) in order to control for Type I error for multiple comparisons. A p‐value less than 0.00625 was considered significant.
3. RESULTS
A total of 57 HS nodules was analysed with D‐OCT from 40 mild‐moderate HS patients of whom 40% were male. Patient's mean age was 33 years (range 11–73) and the mean BMI was 28.3 (range 17–38.1). Time from disease onset varied from 1 to 30 years (average: 8) before enrolment with paediatric onset was reported in 12 patients (30%). Most HS patients were active smokers (58%) and all patients had a history of multiple HS medical or surgical treatments, with subsequent recurrence. Disease severity, according to International Hidradenitis suppurativa Severity Score System (IHS4), 13 ranged from 2 to 20 (mean 9.6) with phlogistic lesions in two body sites for most of the patients (range 1–5). Disease flares were reported with an average of 2.4 episodes every 2 months (range 1–8 episodes). We observed an average value of the visual analogue scale (VAS) for pain of 7.2 (range 4.3–10.0). Data reported are summarized in Table S1.
Dynamic optical coherence tomography images showed that HS nodules compared to healthy skin were typically characterized by one or more hyper‐keratinized infundibula at the top (p < 0.005) and a hypo‐echogenic area in the dermis (Figure 1). The presence of amorphous material inside the infundibula and of an organized inflammatory infiltrate were often observed (p < 0.005). The contour of the dermal–epidermal junction was frequently ill‐defined, probably due to inflammatory phenomena (p < 0.005). Average epidermal thickness was significantly higher in the border of HS nodules (203 μm, SD: 54 μm) compared with healthy skin (128 μm, SD: 19 μm). In D‐OCT en‐face images, the vascular signal of HS nodules was significantly increased with respect to the control group, both at 300 and 500 μm depths (Table 2, Figure 2).
FIGURE 1.
Cross‐sectional OCT image of healthy axillary skin showing a normal epidermal thickness and a well‐defined DEJ (A). Vascular D‐OCT image of healthy control (B) with normal vascularization; Cross‐sectional OCT image of HS nodule characterized by hyper‐keratinization at the level of the infundibulum (blue stars) (C) and corresponding vascular D‐ OCT image showing increased vascular signal (D); Cross‐sectional OCT image of HS nodule showing clots, characterized by amorphous keratinized material inside follicles (green arrowheads) (E) and corresponding vascular D‐OCT image (F); Cross‐sectional OCT image of HS nodule showing increased epidermal thickness, with papillomatosis (white arrows) and blurred DEJ (G). Vascular D‐OCT image of increased epidermal thickness, with enlarged dermal papillae that project into the epidermis (H). Cross‐sectional OCT image of HS nodule characterized by the presence of an organized inflammatory infiltrate, corresponding to a collection of organized hyper‐echogenic inflammatory material in the epidermis and the dermis (pink rhombus) (I) and corresponding D‐OCT image with increased vascular signal (L)
TABLE 2.
D‐OCT features of HS nodules in comparison with healthy control skin from the same body regions
D‐OCT features | Healthy control skin, n = 20 | HS nodules, n = 57 | p‐value* | ||||||
---|---|---|---|---|---|---|---|---|---|
Average | SD | Count | % | Average | SD | Count | % | ||
Vascular threshold at 300 μm | 1755 | 1428 | 13068 | 14943 | <0.001 | ||||
Vascular threshold at 500 μm | 13665 | 8198 | 47523 | 48191 | <0.001 | ||||
Epidermal thickness, mm | 0.1284 | 0.0195 | 0.2033 | 0.0547 | <0.001 | ||||
Infundibular hyper‐keratinization | |||||||||
No | 14 | 70% | 7 | 12.3% | <0.001 | ||||
Yes | 6 | 30% | 50 | 87.7% | |||||
Blurred DEJ | |||||||||
No | 14 | 70% | 16 | 28.0% | <0.001 | ||||
Yes | 6 | 30% | 41 | 71.9% | |||||
Granular epidermis | |||||||||
No | 19 | 95% | 9 | 15.7% | <0.001 | ||||
Yes | 1 | 5% | 48 | 84.2% | |||||
Clots of amorphous material inside follicles | |||||||||
No | 18 | 90% | 15 | 26.3% | <0.001 | ||||
Yes | 2 | 10% | 42 | 73.7% | |||||
Organized inflammatory infiltrate | |||||||||
No | 20 | 100% | 14 | 24.6% | <0.001 | ||||
Yes | 0 | 0% | 43 | 75.4% |
A p‐value less than 0.006 was considered significant due to Bonferroni adjustment.
FIGURE 2.
Clinical image of healthy control showing the absence of inflammation (A) and en‐face D‐OCT image showing a low vessel density, corresponding to low‐threshold, at both 300 and 500 μm (B,C); Clinical image of an HS nodule from FP group of patients (D) and en‐face D‐OCT image showing higher vessel density compared to healthy control at both 300 and 500 μm (E,F). Clinical image of an HS nodule in the bottom part of the image (black arrow) obtained from a patient in the IP group (G) and en face D‐OCT image at 300 and 500 μm showing significantly increased vessel density at 500 μm compared to follicular HS (H,I)
Among the selected population of mild‐moderate HS, 11 patients presented a mainly follicular phenotype (FP) with a longer disease duration (average 13 years) and the presence of inflammatory nodules without the tendency to coalesce, surrounded by open comedones. These patients reported a disease course characterized by a more indolent progression. Ten patients presented a mainly inflammatory phenotype (IP), characterized by a shorter disease duration (average 4 years), the absence of folliculitis/comedones in the affected areas, and the presence of tunnels and coalescing deep‐seated nodules with scarring. Fifteen patients presented a mixed phenotype (MP), presenting both features of the previously described entities. The comparison of D‐OCT images of nodules of FP and IP patients demonstrated a significant difference regarding the vascular threshold of the lesions at 500 μm depth, showing a higher blood flow and microcirculation in the nodules of IP patients with respect to FP patients (Figure 2).
4. DISCUSSION
The characterization of morphological and functional features of HS nodules with OCT may be advantageous for the identification of anatomical and functional modifications to better understand disease pathogenesis and progression and to monitor the efficacy of HS therapy. The clinical appearance of a small, subcutaneous, painful, phlogistic nodules, located in typical or atypical body‐sites, is the initial most common manifestation of HS, especially during the early stages of the disease (Hurley I and II). 10
Dynamic optical coherence tomography images showed that HS nodules are morphologically and functionally significantly different from healthy skin: they present a dome shaped morphology with one or more enlarged infundibula at the top, with amorphous keratin material inside. The epidermis surrounding the nodule is generally thicker with respect to control healthy skin of the same body‐sites and with a granular aspect, plausibly reflecting the presence of psoriasiform acanthosis. 7 Moreover, the contour of the dermal–epidermal junction is less defined, probably due to inflammatory phenomena. 28 In the dermis an anechogenic area is usually seen and, when the nodule is suppurating, the presence of hyperechogenic inflammatory amorphous material, inside the epidermis or in the superficial dermis, could be observed. HS nodules have increased vascular signal as demonstrated by the significant difference of the vascular threshold compared with the control healthy skin, both at 300 and 500 μm depths. This observation, which is explained by the induction of increased dermal blood flow and skin micro‐vascularization caused by the phlogistic processes of HS, gives important information regarding the actual inflammatory status of the disease (Figure 1).
This data is in accordance with previous studies which demonstrated that HS lesions are characterized by widening of pilosebaceous units, the presence of a dermal fluid collection and the observation of a high power‐Doppler ultrasound signal in the proximity of the lesions, which decrease after specific therapy, consistently with the resolution of the inflammatory processes. 29 , 30 , 31 , 32 , 33 In addition, the presence of widened and hyper‐keratinized pilosebaceous units may reflect one of the leading events implicated in HS pathogenesis, which starts with an abnormal infundibular keratizination that causes occlusion and rupture of the follicular ostia. 30 , 34 , 35 Afterwards, HS inflammatory process is known to affect the microcirculation network initiating a remodelling process that ends in a vicious cycle of enhanced inflammation and scarring. 10 , 36
In order to further characterize HS features, we compared nodules from FP and IP patients. This analysis showed a significant difference regarding the vascular threshold at 500 μm depth, implicating that IP nodules present a higher blood flow in the deep dermis with respect to FP nodules. This phenomenon could possibly represent a sign of enhanced inflammatory‐shift of IP disease, with respect to FP, leading to the rapid development of more complex lesions. It is plausible to hypothesize that higher increase of blood flow values in IP nodules may be associated to a stronger local and systemic inflammation, inducing dermal tissue remodelling with subsequent generation of fibrotic processes, scarring, sinus tract formation and an augmented probability of other comorbidities as such as increased cardiovascular risk. 20
Although further studies are required to correlate microscopic features with biologic data, D‐OCT represents a useful tool for the in vivo skin investigation at nearly histologic resolution of HS lesions. In the near future, the morphologic and vascular alterations occurring during the initiation and maintenance of the disease will be monitored through non‐invasive imaging procedures, for the better understanding and management of patients, allowing a precise quantification of therapeutic efficacy, as it has been shown in other inflammatory skin diseases. 22 To the best of our knowledge, Hurley's classification of HS is still the most applied in clinical practice, but it seems to be quite limiting in both diagnosis and follow‐up of patients. Indeed, the identification of different HS phenotypes, through clinical examination and D‐OCT imaging, could improve HS diagnosis and management, especially when atypical localizations or early disease presentation occur. A precocious and more aggressive treatment of HS patients with a rapidly evolving type of disease that corresponds to the IP phenotype is crucial to prevent the appearance of complex scarring with unfavourable disease course.
To conclude, the characterization of HS nodules through D‐OCT image analysis allows to identify specific features associated with infundibular alterations, inflammation and tissue remodelling with neovascularization. The microscopic and functional analysis of early HS lesions with D‐OCT may have important clinical consequences for patient assessment and management, and to non‐invasively monitor treatment efficacy, in order to prevent scarring and disease progression.
CONFLICT OF INTEREST
The authors report no conflict of interest.
AUTHOR CONTRIBUTIONS
Marco Manfredini, Giovanni Pellacani and Vincenzo Bettoli designed the study and wrote the paper. Camilla Chello and Silvana Ciardo collected D‐OCT images and analysed data. Stefania Guida and Johanna Chester collected and elaborated data from literature. Marco Manfredini, Claudia Lasagni, Laura Bigi and Francesca Farnetani enrolled patients in the study and collected clinical data. All the authors have read and approved the final version of the manuscript. Authors declare that all procedures performed involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Supporting information
Tab S1. Epidemiological and clinical features of HS patients.
ACKNOWLEDGEMENTS
The patients in this manuscript have given written informed consent to publication of their case details. Open access funding enabled and organized by CRUI.
Manfredini M, Chello C, Ciardo S, et al. Hidradenitis suppurativa: Morphologic and vascular study of nodular inflammatory lesions by means of optical coherence tomography. Exp Dermatol. 2022;31:1076–1082. doi: 10.1111/exd.14560
Funding information
No funding to declare.
[Correction added on 17 May 2022, after first online publication: CRUI funding statement has been added.]
REFERENCES
- 1. Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158‐164. [DOI] [PubMed] [Google Scholar]
- 2. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of Hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619‐644. [DOI] [PubMed] [Google Scholar]
- 3. Negus D, Ahn C, Huang W. An update on the pathogenesis of Hidradenitis suppurativa: implications for therapy. Exp Rev Clin Immunol. 2018;14:275‐283. [DOI] [PubMed] [Google Scholar]
- 4. Guet‐Revillet H, Jais J‐P, Ungeheuer M‐N, et al. The microbiological landscape of anaerobic infections in Hidradenitis suppurativa: a prospective metagenomic study. Clin Infect Dis. 2017;65:282‐291. [DOI] [PubMed] [Google Scholar]
- 5. Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in Hidradenitis suppurativa. J Invest Dermatol. 2016;136:1768‐1780. [DOI] [PubMed] [Google Scholar]
- 6. von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis*. Exp Dermatol. 2009;19:533‐537. [DOI] [PubMed] [Google Scholar]
- 7. von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367‐371. [DOI] [PubMed] [Google Scholar]
- 8. Nguyen Tv, Damiani G, Orenstein LaV, Hamzavi I, Jemec Gb. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35:50‐61. [DOI] [PubMed] [Google Scholar]
- 9. Bettoli V, Manfredini M, Massoli L, et al. Rates of antibiotic resistance/sensitivity in bacterial cultures of Hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol. 2018;33(5):930‐936. [DOI] [PubMed] [Google Scholar]
- 10. Wolk K, Join‐Lambert O, Sabat R. Aetiology and pathogenesis of Hidradenitis suppurativa. Br J Dermatol. 2020;183:999‐1010. [DOI] [PubMed] [Google Scholar]
- 11. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23:985‐998. [DOI] [PubMed] [Google Scholar]
- 12. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for Hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81:76‐90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401‐1409. [DOI] [PubMed] [Google Scholar]
- 14. Manfredini M, Garbarino F, Bigi L, Pellacani G, Magnoni C. Surgical and post‐surgical wound care in Hidradenitis suppurativa. Dermatol Ther. 2020;33:e13282. [DOI] [PubMed] [Google Scholar]
- 15. Bettoli V, Manfredini M, Calamo G, et al. Long‐term adalimumab treatment of Hidradenitis suppurativa: results and practical insights from a real‐life experience. Dermatol Ther. 2018;31(6):e12737. [DOI] [PubMed] [Google Scholar]
- 16. Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of Hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831‐839. [DOI] [PubMed] [Google Scholar]
- 17. Ingram JR. The epidemiology of Hidradenitis suppurativa. Br J Dermatol. 2020;183:990‐998. [DOI] [PubMed] [Google Scholar]
- 18. van der Zee HH, Jemec GBE. New insights into the diagnosis of Hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol. 2015;73(5 Suppl 1):S23‐S26. [DOI] [PubMed] [Google Scholar]
- 19. Martorell A, Jfri A, Koster SBL, et al. Defining Hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol. 2020;34:1309‐1318. [DOI] [PubMed] [Google Scholar]
- 20. Cuenca‐Barrales C, Montero‐Vilchez T, Salvador‐Rodríguez L, Sánchez‐Díaz M, Arias‐Santiago S, Molina‐Leyva A. Implications of Hidradenitis suppurativa phenotypes in cardiovascular risk and treatment decisions: a retrospective cohort study. Dermatology. 2021;237:727‐732. [DOI] [PubMed] [Google Scholar]
- 21. Garbarino F, Migliorati S, Farnetani F, et al. Nodular skin lesions: correlation of reflectance confocal microscopy and optical coherence tomography features. J Eur Acad Dermatol Venereol. 2020;34:101‐111. [DOI] [PubMed] [Google Scholar]
- 22. Manfredini M, Liberati S, Ciardo S, et al. Microscopic and functional changes observed with dynamic optical coherence tomography for severe refractory atopic dermatitis treated with dupilumab. Skin Res Technol. 2020;26(6):779‐787. [DOI] [PubMed] [Google Scholar]
- 23. Guida S, Longhitano S, Ardigò M, et al. Dermoscopy, confocal microscopy and optical coherence tomography features of main inflammatory and autoimmune skin diseases: a systematic review. Australas J Dermatol. 2021;63(1):15‐26. [DOI] [PubMed] [Google Scholar]
- 24. Manfredini M, Greco M, Farnetani F, et al. Acne: morphologic and vascular study of lesions and surrounding skin by means of optical coherence tomography. J Eur Acad Dermatol Venereol. 2017;31:1541‐1546. [DOI] [PubMed] [Google Scholar]
- 25. Manfredini M, Bettoli V, Sacripanti G, et al. The evolution of healthy skin to acne lesions: a longitudinal, in vivo evaluation with reflectance confocal microscopy and optical coherence tomography. J Eur Acad Dermatol Venereol. 2019;33:1768‐1774. [DOI] [PubMed] [Google Scholar]
- 26. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846‐855. [DOI] [PubMed] [Google Scholar]
- 27. Ulrich M, Themstrup L, de Carvalho N, et al. Dynamic optical coherence tomography in dermatology. Dermatology (Basel, Switzerland). 2016;232:298‐311. [DOI] [PubMed] [Google Scholar]
- 28. von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19:533‐537. [DOI] [PubMed] [Google Scholar]
- 29. Wortsman X. Color Doppler ultrasound: a standard of care in Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34:e616‐e617. [DOI] [PubMed] [Google Scholar]
- 30. Wortsman X. Strong validation of ultrasound as an imaging biomarker in Hidradenitis suppurativa. Br J Dermatol. 2021;184:591‐592. [DOI] [PubMed] [Google Scholar]
- 31. Caposiena Caro RD, Solivetti FM, Bianchi L. Power Doppler ultrasound assessment of vascularization in Hidradenitis suppurativa lesions. J Eur Acad Dermatol Venereol. 2018;32:1360‐1367. [DOI] [PubMed] [Google Scholar]
- 32. Caposiena Caro RD, Solivetti FM, Candi E, Bianchi L. Clinical and Power‐Doppler ultrasound features related with persistence of fistulous tracts under treatment with adalimumab in Hidradenitis suppurativa: 4 years of follow‐up. Dermatol Ther. 2021;34:e14804. [DOI] [PubMed] [Google Scholar]
- 33. Martorell A, Alfageme Roldán F, Vilarrasa Rull E, et al. Ultrasound as a diagnostic and management tool in Hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol. 2019;33:2137‐2142. [DOI] [PubMed] [Google Scholar]
- 34. Wortsman X, Moreno C, Soto R, Arellano J, Pezo C, Wortsman J. Ultrasound in‐depth characterization and staging of Hidradenitis suppurativa. Dermatol Surg. 2013;39:1835‐1842. [DOI] [PubMed] [Google Scholar]
- 35. Cappilli S, Giovanardi G, Di Stefani A, et al. Real‐time confocal imaging for Hidradenitis suppurativa: description of morphological aspects and focus on the role of follicular ostia. Dermatology. 2021;237:705‐711. [DOI] [PubMed] [Google Scholar]
- 36. Frew JW, Navrazhina K, Marohn M, Lu P‐JC, Krueger JG. Contribution of fibroblasts to tunnel formation and inflammation in Hidradenitis suppurativa/acne inversa. Exp Dermatol. 2019;28:886‐891. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Tab S1. Epidemiological and clinical features of HS patients.